Clinical Trial Update: Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update on subcutaneous epcoritamab, with or without lenalidomide, as first-line therapy for diffuse large B-cell lymphoma; the study is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Epcoritamab (epcoritamab)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: Genmab | Conditions: Diffuse Large B-Cell Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING